SLC12A5 and cancer: Although there was no statistically significant survival difference between KCC2 mutation and the wild-type (WT) group (p < 0.05), we found that NKCC1MUT could prominently prolong DSS (p = 0.019), PFS (p = 2.59e-04), and OS (p = 0.034) compared with NKCC1WT cancer patients.